Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
Montor, Wagner Ricardo
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. [electronic resource] - Molecular cancer 02 2018 - 55 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1476-4598
10.1186/s12943-018-0792-2 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Biomarkers, Tumor
Clinical Trials as Topic
Drug Discovery
Drug Resistance, Neoplasm
Humans
Molecular Targeted Therapy
Mutation
Neoplasms--drug therapy
Protein Binding
Protein Kinase Inhibitors--pharmacology
Receptor Protein-Tyrosine Kinases--antagonists & inhibitors
Signal Transduction--drug effects
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. [electronic resource] - Molecular cancer 02 2018 - 55 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1476-4598
10.1186/s12943-018-0792-2 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Biomarkers, Tumor
Clinical Trials as Topic
Drug Discovery
Drug Resistance, Neoplasm
Humans
Molecular Targeted Therapy
Mutation
Neoplasms--drug therapy
Protein Binding
Protein Kinase Inhibitors--pharmacology
Receptor Protein-Tyrosine Kinases--antagonists & inhibitors
Signal Transduction--drug effects